Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
“Recursion has spent the last 10 years building one of the world’s largest biological and chemical datasets, along with automated wet-lab and dry-lab tools that empower our scientists to move quickly to decode biology to discover and rapidly advance promising programs,” said
LOWE was developed at
- Foundation models that accurately represent or simulate the biological and chemical worlds of drug discovery
- Inference engines and active learners to formulate hypotheses and learn from results
- Orchestration and reasoning systems like LOWE that can design and execute experiments for hypothesis testing
To learn more about LOWE, visit recursion.com/lowe.
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in
Having bested industry giants in machine learning competitions and after gaining a deeper understanding of drug discovery intricacies, they teamed up with Recursion to combine Valence’s models with Recursion’s fit-for-purpose datasets to make better predictions and choose better experiments with a lower failure rate, at greater speed, and at a lesser cost. Combining the intellectual freedom of academia with the resources and stability of industry,
This document contains information that includes or is based upon "forward-looking statements'' within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding early and late stage discovery, preclinical, and clinical programs, including timelines for data readouts; licenses and collaborations, including option exercises by partners and additional partnerships; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance, including cash runway; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “could,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the
Media Contact Media@Recursion.com Investor Contact Investor@Recursion.com